论文部分内容阅读
目的:本次浅析哮喘性支气管炎的治疗体会。方法:选取于2013年5月至2014年5月在该院接受治疗的哮喘性支气管炎患者90例作为本次研究对象,按照随机抽取的方式将所有患者分为实验组和对照组各45例,对照组:给予常规治疗;实验组:常规治疗基础上给予雾化吸入治疗。结果:实验组总有效率为93.33%,对照组总有效率为75.56%,P<0.05,具有统计学意义;实验组接受联合治疗后,其FEVI为(2.97±0.35)L,明显优于对照组的[(2.22±0.68)L,P<0.05];实验组FVE为3.13±0.48L,明显优于对照组的[(2.72±0.77)L,P<0.05];实验组PEER为(6.10±0.29)L/s,明显优于对照组的[(4.02±1.27)L/s,P<0.05]。结论:常规治疗基础上给予雾化吸入治疗哮喘性支气管炎,能够使得患者咳嗽、气促等临床症状得到显效改善,同时改善患者用力吸气量(FEVI)、FVE及呼气高峰流量(PEER)等临床指标,能够减轻患者的痛苦,帮助患者提高生活质量,是可以信赖的治疗方法,值得在临床上大力推广。
Objective: This analysis of asthma bronchitis treatment experience. Methods: Ninety patients with asthmatic bronchitis treated in our hospital from May 2013 to May 2014 were selected as the study subjects. All patients were randomly divided into experimental group and control group of 45 cases , Control group: given conventional treatment; experimental group: conventional treatment based on atomization inhalation therapy. Results: The total effective rate in the experimental group was 93.33%, the total effective rate in the control group was 75.56%, P <0.05, which was statistically significant. The FEVI of the experimental group was (2.97 ± 0.35) L, which was significantly better than the control group (2.22 ± 0.77) L, P <0.05). The PEER in the experimental group was (6.22 ± 0.68) L, P <0.05 compared with the control group 0.29) L / s, which was significantly better than that of the control group [(4.02 ± 1.27) L / s, P <0.05]. Conclusion: The treatment of asthmatic bronchitis by inhalation based on conventional therapy can improve the clinical symptoms such as cough, shortness of breath and improve the FEVI, FVE and PEER, And other clinical indicators, can reduce the suffering of patients and help patients improve the quality of life, is a reliable treatment, it is worth to clinically vigorously promote.